Wilmington, DE, United States of America

Gerard R Klinzing

This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2020.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Gerard R Klinzing

Introduction

Gerard R Klinzing is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of HIV infection. With a total of 2 patents to his name, Klinzing's work has had a meaningful impact on medical science.

Latest Patents

Klinzing's latest patents include pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate, and lamivudine. These compositions are designed for the treatment of HIV infection. The patents also disclose processes for making these pharmaceutical compositions, showcasing Klinzing's innovative approach to addressing critical health issues.

Career Highlights

Throughout his career, Klinzing has worked with prominent companies such as Merck Sharp & Dohme Corporation and Merck Sharp & Dohme Corp. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in pharmaceutical technology.

Collaborations

Klinzing has collaborated with talented individuals in his field, including Santipharp Panmai and Aditya Tatavarti. These partnerships have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Gerard R Klinzing's contributions to pharmaceutical inventions demonstrate his commitment to improving healthcare. His patents reflect a dedication to innovation that addresses significant medical challenges.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…